logo

Pluristem Therapeutics, Inc. (PSTI)



Trade PSTI now with
  Date
  Headline
10/16/2018 7:02:59 AM Pluristem Therapeutics: FDA Approves Cost Recovery For PLX-PAD Under Expanded Access Program In Critical Limb Ischemia
10/10/2018 7:10:23 AM Pluristem Therapeutics Announces Publication In JCSM Of Two-Year Follow-Up Data From Phase I/II Study Of PLX-PAD
9/25/2018 5:33:48 AM Pluristem Therapeutics Says FDA Granted Orphan Drug Designation To PLX Cell Therapy
8/8/2018 7:04:27 AM Pluristem Begins Two Pivotal Phase III Studies In Israel
6/28/2018 7:06:08 AM BiondVax Appoints Mark Germain As Vice-Chairman Of Its Board
6/25/2018 7:07:37 AM Pluristem, Fukushima University Report Positive Data Of PLX-R18 Cells For Radiation Damage To GI Tract And Bone Marrow
6/12/2018 6:03:07 AM Pluristem Reports Positive Top-Line Results From Its Multinational Phase II Intermittent Claudication Study
6/4/2018 6:00:37 AM Pluristem To Announce Top-Line Results Of Its Multinational Phase II Intermittent Claudication Study On June 12, 2018
4/30/2018 7:13:31 AM U.S. FDA Clears Pluristem’s IND To Treat Victims Exposed To Acute Radiation
4/25/2018 7:14:46 AM FDA Clears Pluristem’s Phase III Study In Treatment Of Muscle Injury Following Hip Fracture Surgery
3/26/2018 7:06:46 AM Roger Jeffs, Former Co-CEO Of United Therapeutics, Joins Pluristem's Strategic Advisory Board
1/9/2018 7:09:18 AM FDA Clears Pluristem' EAP For Use Of PLX-PAD Cell Treatment In Patients With Critical Limb Ischemia
12/12/2017 5:30:38 AM Pluristem Receives A GMP Certification And Manufacturer/importer Authorization From Israel’s Ministry Of Health
12/7/2017 5:17:53 AM Pluristem To Present Data From Its Phase II-equivalent Study Of PLX-R18 Cells For Treatment Of Acute Radiation Syndrome
11/6/2017 7:23:17 AM Pluristem Agrees With Tel Aviv Sourasky Medical Center To Conduct Phase I/II Trial In Steroid-Refractory Chronic GvHD
10/19/2017 7:37:52 AM Pluristem: FDA Grants Orphan Drug Designation For PLX-R18 Cell Therapy For Acute Radiation Syndrome
10/16/2017 7:08:46 AM Pluristem Therapeutics Says New Data Highlights Potential Of PLX Cells In Improving Cardiac Function In Diabetes
10/2/2017 7:12:11 AM Pluristem Therapeutics Says $7.9 Mln Granted To NTRACK Collaborative Project Designed To Study PLX-PAD Cells
9/18/2017 7:04:03 AM FDA Grants Fast Track Designation To Pluristem's PLX-PAD For Treatment Of Critical Limb Ischemia